Transformative Therapies For Retinal Diseases


Our Pipeline

Learn More

CLINICAL TRIALS

Learn More

INVESTOR OVERVIEW

Learn More

Our Story

Iveric Bio is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs.

Who We Are


An experienced, passionate team with a proven track record in collaborative clinical development and commercialization of novel therapies. Our team is focused on delivering strategic solutions that better the lives of patients, eyecare professionals, and more. With expertise in ophthalmology and retinal diseases, we welcome the challenges of the future.

Read More

What We're Doing


Our strategy is focused on developing multiple, complementary assets to treat a broad spectrum of retinal diseases. We intend to do this by potentially studying Zimura in indications beyond geographic atrophy secondary to dry AMD and autosomal recessive Stargardt disease and by advancing the development of IC-500 our HtrA1 inhibitor.

Having both Zimura and IC-500 in our pipeline positions us to potentially provide treatments for patients with various types and stages of AMD, the leading cause of vision loss in the elderly. We are also developing novel gene therapy technology to treat orphan inherited retinal diseases (IRDs). IRDs can be caused by many different mutations of a single gene. Our strategy is to develop mutation independent treatment options to potentially treat the entire group of patients with a particular IRD.

Read More

Many Perspectives, One Vision.

We are a collection of inquisitive minds leveraging decades of clinical expertise and marketing knowledge. Discover more about our experience, and what makes Iveric Bio unique, by clicking the photos below.

Leadership

Glenn P. Sblendorio

Chief Executive Officer

Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

Pravin U. Dugel, MD

President

Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona.

Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, Nepal, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA. Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame.

Dr Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has consulted for over 50 companies and has served on the Aerpio Therapeutics board of directors.

Dr. Dugel has been a member of the board of directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery. In Arizona, Dr. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness.

Dr. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. He graduated Summa cum Laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. He was also captain of the Columbia Squash team. He then attended UCLA School of Medicine, then residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. Michels Foundation Fellowship award.

Tony Gibney

Chief Business and Strategy Officer

Tony Gibney is Executive Vice President and Chief Business and Strategy Officer of Iveric Bio. Mr. Gibney is an experienced biotechnology executive and former investment banker with over 25 years of experience dedicated to advising biotechnology companies. Before joining Iveric Bio, Mr. Gibney served as Chief Financial Officer and Chief Business Officer at Fog Pharmaceuticals overseeing the business development, strategy and finance functions of the company. Previously, Mr. Gibney was Executive Vice President and Chief Business Officer at Achillion Pharmaceuticals, where he led the successful sale of Achillion to Alexion Pharmaceuticals in 2020. Before Achillion, Mr. Gibney was a Managing Director and Co-Head of the Biotechnology Investment Banking Team at Leerink Partners LLC, and Managing Director of Merrill Lynch’s Healthcare Group. Mr. Gibney has executed over 150 financings and merger and acquisition advisory transactions for U.S. and European clients. He earned a B.A. in Economics and a B.A. in History from Yale University.

Todd D.C. Anderman

Chief Legal Officer and Corporate Secretary

Todd D.C. Anderman is Chief Legal Officer & Corporate Secretary of Iveric Bio. Mr. Anderman joined the Company in 2015 after representing the Company since 2012 while practicing corporate law at Wilmer Cutler Pickering Hale and Dorr LLP. While at WilmerHale, Mr. Anderman’s practice focused on representing life sciences and technology companies. Mr. Anderman began his career as a corporate attorney at Cravath, Swaine & Moore LLP. Mr. Anderman has extensive experience advising on merger, acquisition, divestiture, licensing, and financing transactions. Mr. Anderman received his BA in government and philosophy from the College of Arts & Sciences at Cornell University and his JD from the University of Pennsylvania Law School.

David F. Carroll

Chief Financial Officer

David Carroll, M.B.A, is the Chief Financial Officer of Iveric Bio. Mr. Carroll joined the Company in 2016 and has more than 25 years of experience in the life sciences industry. Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller, and most recently, Senior Vice President, Chief Accounting Officer. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb. Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.

Xiao-Ping Dai, PhD

Chief Technical Officer

Dr. Xiao-Ping Dai is Chief Technical Officer of Iveric Bio, responsible for manufacturing and CMC development of the product pipeline. She joined the company in 2019.

Dr. Dai has more than 20 years of experience in the biopharmaceutical industry, specialized in product and process development and manufacturing. She has successfully developed processes and managed overall CMC development for more than 30 different biological products including monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, multi-specific antibodies and vaccines, from preclinical development through commercialization, including Opdivo and Yervoy. Dr. Dai has a proven track record of internal and external development, with CDMOs/CMOs, managing multiple partnerships and collaborations, technology transfers, scale-ups, process performance qualifications (PPQ) and regulatory filings.

Prior to joining Iveric Bio, Dr. Dai was Chief Technologist and VP of Process and Technology Development at WuXi Advanced Therapy, a CDMO where she built and led an organization engaged in process and technology platform development, serving cell and gene therapy clients. Prior to joining WuXi, Dr. Dai was Sr. Director of Biologics Development and Manufacturing at Celgene Corporation, where she built and led a strong technical team and successfully delivered on multiple internal and external programs. Prior to Celgene, Dr. Dai had over 13 years of effective functional and cross-functional leadership and technical experience in Biologics Development at BMS, Medarex and Regeneron Pharmaceuticals, and before that at NJIT, where she received her PhD in Chemical Engineering.

Dhaval Desai, PharmD

Chief Development Officer

Dhaval Desai, PharmD, is Senior Vice-President and Chief Development Officer at Iveric Bio. Dr. Desai joined Iveric Bio as Chief of Staff in 2020 after serving as Vice President and Medical Unit Head of US Ophthalmics at Novartis. During his time at Novartis, Dr. Desai was responsible for the establishment of a US Ophthalmics unit and developing a comprehensive franchise strategy. Prior to Novartis, Dr. Desai held multiple leadership roles in ophthalmology-focused companies including Aerpio Pharmaceuticals, where he served as Vice President of Medical Affairs and Chief Strategic Officer, and ThromboGenics, where he served as Global Director, Medical Affairs. Dr. Desai received his PharmD and completed his post-doctoral fellowship at Rutgers University.

Kathy Galante

Investor Relations

Kathy Galante is Senior Vice President, Investor Relations at Iveric Bio. Ms. Galante joined the Company in 2013 and has more than 25 years of investor relations experience in the biotechnology industry. Prior to Iveric Bio, Ms. Galante was a Senior Vice President at Burns McClellen, where she was responsible for creating and implementing investor relations programs for both publicly traded and privately held life science companies. Before that, Ms. Galante spent more than two decades at then Nasdaq-listed OSI Pharmaceuticals, where she was instrumental in the development of the company’s investor relations and corporate communications strategy, as well as managing public relations around the launch of Tarceva®. During her tenure at OSI Pharmaceuticals, Ms. Galante was a key member of the management team that transformed a small, $200 million research-based biotechnology company into a profitable, $4 billion biopharmaceutical organization with discovery, development, and commercialization capabilities.

Evelyn Harrison

Chief Clinical Operations Officer

Evelyn Harrison, MBA, is the Senior Vice President & Chief Clinical Operations Officer of Iveric Bio. She brings more than 33 years of management and clinical research experience. Prior to joining Iveric Bio, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Ms. Harrison played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a BA degree in biology from Hofstra University and an MBA from Manhattan College.

Snehal Shah, PharmD

Chief Regulatory & Product Strategy Officer

Dr. Snehal Shah is Senior Vice President, Chief Regulatory & Product Strategy Officer at Iveric Bio. Dr. Shah brings over 18 years of global experience in Regulatory Affairs, Pharmacovigilance and Product Strategy, gained at leading pharmaceutical companies including Hoffmann La-Roche/ Genentech, Noven Pharmaceuticals (Member of the Hisamitsu Group) and Kyowa Kirin.

Dr. Shah has led both biologics and small molecule development programs focusing on rare orphan diseases, oncology, neurology, virology, transplantation, inflammation, endocrinology, and women’s health; at all product lifecycle phases through commercialization. Most notably Dr. Shah has provided strategic leadership to successfully bring over a dozen market applications from filing through approval, allowing new treatment options for patients. This includes first in class treatments for rheumatoid arthritis, vasomotor symptoms associated with menopause, cutaneous T-cell lymphoma, and Parkinson’s disease.

Dr. Shah holds a B.S. in pharmacy from Rutgers University and a Doctorate of Pharmacy from the University of Kansas. He also completed the American Course of Drug Development and Regulatory Sciences Certification program at the University of California, San Francisco.

Amy Sheehan

Chief Human Resources Officer

Amy Sheehan is the Senior Vice President & Chief Human Resources Officer at Iveric Bio. Ms. Sheehan joined the Company in 2014 and brings over 20 years of human resources experience in the biotechnology and manufacturing industries. Prior to joining Iveric Bio Ms. Sheehan led Human Resources for the Electronic Systems Division of Parker Hannifin, a publicly traded Fortune 250 global company. Earlier in Ms. Sheehan’s career she held leadership positions of increasing responsibility in human resources at OSI Pharmaceuticals, a publicly traded biotechnology company. Throughout Ms. Sheehan’s career she oversaw Human Resources teams and led successful HR strategies in talent acquisition, culture, total rewards, leadership development, and training. She holds a MS in human resources management and a BA in psychology from Hofstra University.

Chris Simms

Chief Commercial Officer

Chris Simms is Senior Vice President and Chief Commercial Officer of Iveric Bio. Mr. Simms is an accomplished healthcare leader with more than 20 years of diverse commercial leadership experience at Johnson & Johnson, Genentech, and Novartis, including focused experience in retina, ophthalmology, and optometry. Most recently, he was the Vice President and Head of the Novartis US Ophthalmics business unit which includes the brands BEOVU® and Xiidra®. He joined Novartis in 2017 to build the commercial launch strategy for BEOVU® after leading commercial efforts on Lucentis® at Genentech. Prior to Genentech, he spent 16 years at Johnson & Johnson working with leading brands across their vision care, diabetes and consumer goods businesses in Canada, Japan, and the US. Mr. Simms has a Bachelor of Commerce from Memorial University of Newfoundland and an MBA from York University, Toronto, Canada.

Keith Westby

Chief Operating Officer

Keith Westby is Senior Vice President and Chief Operating Officer of Iveric Bio. Mr. Westby joined the Company in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations. Prior to joining the Company, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a BS in applied physics from the State University of New York, College at Geneseo, a MS in engineering management from Drexel University, and a MBA degree from Columbia Business School.

Board of Directors

Adrienne L. Graves, PhD

Chairman of the Board, Former Chief Executive Officer, Santen. Inc.

Adrienne Graves, Ph.D. – Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. As the former CEO of Santen Inc., she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization, and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical Development (US, Europe, and Japan) for 7 years and CEO for 8 years. Prior to Santen, she spent 9 years at Alcon, joining as Sr. Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as an Independent Director on the boards of Iveric Bio, Qlaris Bio, Nicox S.A., Surface Ophthalmics, Oxurion, TherOptix, and Greenbrook TMS. She previously held board positions at Encore Vision (2011 – 2017; acquired by Novartis), Envisia Therapeutics (2014 – 2017; assets acquired by Aerie Pharmaceuticals), TearLab Corporation (2005 – 2018), Aerpio Therapeutics (2012 – 2017), and Akorn (2012 – 2020). Dr. Graves also serves as Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB), and the RD (Retinal Degeneration) Fund. Dr. Graves co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders). Her recent honors include the Visionary Award from Foundation Fighting Blindness, the Catalyst Award from Glaucoma Research Foundation, the Visionary Award from OWL, the Bernice Brown Memorial Lecture and award from Women in Ophthalmology, and The Ophthalmologist 2021 Power List. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Psychobiology/Neuroscience from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.

Mark S. Blumenkranz, MD

HJ Smead Professor Emeritus, Department of Ophthalmology, Stanford University

Mark S. Blumenkranz, MD, MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University, where he is the co-director of the Ophthalmic Innovation Program. Dr. Blumenkranz is a co-founder and the Chief Executive Officer and Chairman of Kedalion Therapeutics and currently serves as a director of Verana Health, BVI Visitec, Combangio Corporation, and One Medical (ONEM:NASDAQ). Dr. Blumenkranz is also a Managing Director of Lagunita Biosciences, an early stage biotechnology and medical investment company and incubator.

He was a co-founder and served on the boards of Optimedica Corporation (acquired by AMO), Peak Surgical (acquired by Medtronics), Adverum Biotechnologies (ADVM:NASDAQ), and Oculeve (acquired by Allergan). He also co-founded Verana Health (formerly Digisight Technologies) and Combangio Corporation, both clinical-stage privately held venture-backed companies in Silicon Valley, and continues to serve on their boards. In the past he served as an independent Director at Oculex Pharmaceuticals (acquired by Allergan), and Presbia.

Dr. Blumenkranz has a longstanding interest and expertise in university corporate technology transfer and early stage biomedical company formation and is the author of more than 160 peer-reviewed articles and more than 18 issued patents including the Pascal and Catalys lasers. He is a past president of the American University Professors of Ophthalmology, the Retina Society, the Macula Society, and a Fellow Emeritus of the Corporation of Brown University, where he served as the Chair of the Medical School Committee.

Dr. Blumenkranz received his undergraduate, graduate, and medical degrees at Brown; his ophthalmic residency training at Stanford; and a fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute. He served as the Chair of the Ophthalmology Department at Stanford from 1997 until 2015 and played a leading role in the planning, fundraising, and construction of the Byers Eye Institute there.

Axel Bolte

President and CEO, Inozyme Pharma, Inc.

Mr. Bolte has served as a member of our board of directors since August 2007. Since February 2017, Mr. Bolte has served as president and chief executive officer of Inozyme Pharma Inc., a publicly traded biotechnology company. Mr. Bolte previously served as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. From February 2017 to September 2019, Mr. Bolte served as a venture partner to HBM Partners AG, a provider of investment advisory services in the life sciences industry, and where he previously served as an investment advisor from March 2003 through January 2017. From March 2001 to February 2003, Mr. Bolte was an investment manager of NMT New Medical Technologies AG, a Swiss venture capital company focused on life sciences. Prior to joining NMT New Medical Technologies AG, Mr. Bolte served as a scientist at Serono SA, a biotechnology company. Mr. Bolte currently serves on the board of directors of Nabriva Therapeutics AG and previously served on the board of directors of PTC Therapeutics, Inc., both of which are publicly traded biotechnology companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an MBA from the University of St. Gallen, Switzerland.

Pravin U. Dugel, MD

President

Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona.

Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, Nepal, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA. Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame.

Dr Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has consulted for over 50 companies and has served on the Aerpio Therapeutics board of directors.

Dr. Dugel has been a member of the board of directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery. In Arizona, Dr. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness.

Dr. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. He graduated Summa cum Laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. He was also captain of the Columbia Squash team. He then attended UCLA School of Medicine, then residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. Michels Foundation Fellowship award.

Jane Pritchett Henderson

Chief Financial Officer, Apogee Therapeutics

Jane Pritchett Henderson has more than 32 years of experience in the life sciences industry and health care investment banking. She currently serves as Chief Financial Officer at Apogee Therapeutics, a company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Previously Ms. Henderson served as Chief Financial Officer at Adagio Therapeutics, a company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. Prior to Adagio, Ms. Henderson served as Chief Financial Officer at Turnstone Biologics, a clinical-stage immuno-oncology company. Prior to Turnstone, Ms. Henderson served as CFO and Senior Vice President of Corporate Development at Voyager Therapeutics, a publicly-traded, clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc. in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., until ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of Akero Therapeutics, a publicly traded, clinical-stage company focused on NASH.

Christine Ann Miller

President and Chief Executive Officer, Melinta Therapeutics

Christine Ann Miller has served as President and Chief Executive Officer and as a member of the board of Melinta Therapeutics since August 2020. Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. Most recently, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was accountable for transitioning the portfolio toward- rapid-growth and higher-margin segments, such as complex generics and value-added medicines, while continuing to build the branded generics business.

Among her various achievements, Ms. Miller directed more than 50 product launches that generated over $300 million of new annual revenue, closed numerous business development acquisitions, and built a robust five-year development and acquisition product pipeline. Before Sandoz, Ms. Miller spent over a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals where she led the preparation of numerous product launches and held leadership roles in both R&D operations and supply chain management.

Ms. Miller started her career at Merck as a chemical engineer and procurement analyst and earned an MBA and a Master’s in Technology Management at Stevens Institute of Technology and a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute.
Ms. Miller’s leadership focus combines her passion for building and leading high performing teams with goal-driven operational rigor. She articulates a clear mission, vision and strategy that engages people to cohesively work towards creative problem solving and innovative solutions.
She serves as an Advisory Board Member for the Healthcare Businesswomen’s Association and is a frequent panelist and speaker at industry events.

Calvin Roberts, MD

President and CEO, Lighthouse Guild

Calvin W. Roberts, MD is a renowned specialist in cataract and refractive surgery. Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. Dr. Roberts is the President and CEO of Lighthouse Guild, the leading provider of services to those with vision loss. Formerly, Dr. Roberts served as Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts has been a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a founding member of the board of directors of Alimera Sciences. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson, and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals.

Dr. Roberts received an AB from Princeton University and his MD from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.

Glenn P. Sblendorio

Chief Executive Officer Iveric Bio

Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

What's Going On?

Keep up-to-date with the latest news about Iveric Bio and its clinical developments.

  • 2023
  • 2022
  • 2021
  • 2020
06/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jun. 2, 2023-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on May 19, 2023 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
Posted: June 02, 2023
Read More
05/24
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--May 24, 2023-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on May 19, 2023 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 63 newly-hired, non-executive employees.
Posted: May 24, 2023
Read More
04/30
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023 - -Acquisition advances Astellas’ Primary Focus on “Blindness & Regeneration ”- -Acquisition price of US$40 per share in
Posted: April 30, 2023
Read More
04/23
Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting
- Post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol (ACP) was correlated with reduced geographic atrophy (GA) growth - - Post-hoc time-to-event analyses signal fewer patients receiving ACP had 10-, 15- and
Posted: April 23, 2023
Read More
04/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Apr. 4, 2023-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on April 3, 2023 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
Posted: April 04, 2023
Read More
03/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Mar. 2, 2023-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 1, 2023 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
Posted: March 02, 2023
Read More
03/01
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
- FDA Accepts Filing of New Drug Application and Grants Priority Review for Avacincaptad Pegol (ACP) for the Treatment of Geographic Atrophy; PDUFA Goal Date is August 19, 2023 - - Post-hoc Time-to-Event Analysis of ACP GATHER Trials Signals up to 59% Risk Reduction in Rate of Vision Loss Compared
Posted: March 01, 2023
Read More
03/01
Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials
- Post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months - - Analysis to be presented at the ARVO Annual Meeting from April 23-27, 2023 - PARSIPPANY, N.J. --(BUSINESS WIRE)--Mar. 1, 2023-- IVERIC bio, Inc.
Posted: March 01, 2023
Read More
02/28
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
PARSIPPANY, N.J. --(BUSINESS WIRE)--Feb. 28, 2023-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7,
Posted: February 28, 2023
Read More
02/22
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
PARSIPPANY, N.J. --(BUSINESS WIRE)--Feb. 22, 2023-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023 . Following the announcement, the Iveric Bio management team will host a live
Posted: February 22, 2023
Read More
02/16
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
- PDUFA goal date is August 19, 2023 - PARSIPPANY, N.J. --(BUSINESS WIRE)--Feb. 16, 2023-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for avacincaptad pegol
Posted: February 16, 2023
Read More
02/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Feb. 2, 2023-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on February 1, 2023 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees.
Posted: February 02, 2023
Read More
01/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jan. 4, 2023-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on January 3, 2023 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to twelve newly-hired, non-executive employees.
Posted: January 04, 2023
Read More
01/03
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jan. 3, 2023-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio , to its Board of Directors, effective as of January 1, 2023 . Dr. Dugel has been instrumental in helping to shape the Company’s business
Posted: January 03, 2023
Read More
12/20
Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
- Commercial launch preparations continue to accelerate - PARSIPPANY, N.J. --(BUSINESS WIRE)--Dec. 20, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling
Posted: December 20, 2022
Read More
12/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Dec. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
Posted: December 02, 2022
Read More
11/30
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
PARSIPPANY, N.J. --(BUSINESS WIRE)--Nov. 30, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and
Posted: November 30, 2022
Read More
11/30
Iveric Bio Announces Proposed Offering of Common Stock
PARSIPPANY, N.J. --(BUSINESS WIRE)--Nov. 30, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a
Posted: November 30, 2022
Read More
11/17
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
- Designation based on 12-month primary endpoint data from GATHER pivotal trials - - Avacincaptad pegol (ACP) is the only investigational product for treatment of GA to achieve two positive phase 3 pivotal trials with statistical significance - - In GATHER clinical program, ACP achieved observed
Posted: November 17, 2022
Read More
11/04
Iveric Bio to Present at Upcoming Investor Conferences
PARSIPPANY, N.J. --(BUSINESS WIRE)--Nov. 4, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Iveric Bio management will participate in fireside chats at the following investor conferences in November: Credit Suisse   31 st Annual Healthcare Conference 2022 Date: November 9, 2022 Time:
Posted: November 04, 2022
Read More
11/03
Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
PARSIPPANY, N.J. --(BUSINESS WIRE)--Nov. 3, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the first part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP, also known as Zimura®) a novel
Posted: November 03, 2022
Read More
11/03
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
- Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - - Planned NDA Submission Moved Up to End of This Year - - Received Favorable Feedback from FDA on Intermediate AMD Development Plan - - Conference Call and Webcast Today, November 3, 2022 , at 8:00 a.m.
Posted: November 03, 2022
Read More
11/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Nov. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on November 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.
Posted: November 02, 2022
Read More
10/27
Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022
PARSIPPANY, N.J. --(BUSINESS WIRE)--Oct. 27, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022 . Following the announcement, the Iveric Bio management team will host a live conference call
Posted: October 27, 2022
Read More
10/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Oct. 4, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on October 3, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.
Posted: October 04, 2022
Read More
09/27
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
  PARSIPPANY, N.J. --(BUSINESS WIRE)--Sep. 27, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of avacincaptad pegol (ACP, also known as Zimura ® ), an investigational complement C5 inhibitor
Posted: September 27, 2022
Read More
09/07
Iveric Bio to Present at Upcoming Investor Conferences
PARSIPPANY, N.J. --(BUSINESS WIRE)--Sep. 7, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in fireside chats at the following two investor conferences in September: Wells Fargo 2022
Posted: September 07, 2022
Read More
09/06
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area - - Statistically Significant Result with Favorable Safety Profile - - Post-hoc
Posted: September 06, 2022
Read More
09/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Sep. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.
Posted: September 02, 2022
Read More
08/10
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
PARSIPPANY, N.J. --(BUSINESS WIRE)--Aug. 10, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, “Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE,” at the H.C.
Posted: August 10, 2022
Read More
08/03
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022
PARSIPPANY, N.J. --(BUSINESS WIRE)--Aug. 3, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer, and Keith Westby , Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August
Posted: August 03, 2022
Read More
08/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Aug. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on August 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.
Posted: August 02, 2022
Read More
07/26
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results
- Zimura ® GATHER2 Topline Data Expected in September of this Year- - GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% – - Agreement for up to $250 Million in Non-dilutive Debt Financing Secured - - Exclusive License Entered into for
Posted: July 26, 2022
Read More
07/26
Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jul. 26, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million
Posted: July 26, 2022
Read More
07/21
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jul. 21, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022 . Following the announcement, the Iveric Bio management team will host a live conference call and
Posted: July 21, 2022
Read More
07/16
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jul. 16, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that in a post-hoc analysis from the GATHER1 clinical trial, Zimura showed a reduction of geographic atrophy lesion growth, compared to sham, across all distances from the foveal center point.
Posted: July 16, 2022
Read More
07/05
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®
PARSIPPANY, N.J. & TURKU, Finland --(BUSINESS WIRE)--Jul. 5, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd , announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura ® (avacincaptad pegol) using
Posted: July 05, 2022
Read More
07/01
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jul. 1, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on July 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee.
Posted: July 01, 2022
Read More
06/10
Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jun. 10, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today a post-hoc analysis from the Zimura ® (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change
Posted: June 10, 2022
Read More
06/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Jun. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on June 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.
Posted: June 02, 2022
Read More
05/17
Iveric Bio to Present at the UBS Global Healthcare Conference 2022
PARSIPPANY, N.J. --(BUSINESS WIRE)--May 17, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on Monday, May 23, 2022 , at 10:45 a.m. Eastern Time .
Posted: May 17, 2022
Read More
05/16
Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference
PARSIPPANY, N.J. --(BUSINESS WIRE)--May 16, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present a corporate overview at the H.C. Wainwright Global Investment Conference , being held from May 23-26, 2022 .
Posted: May 16, 2022
Read More
05/04
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results
- Zimura ® GATHER2 Topline Data Expected in the Third Quarter of this Year- - GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90% – - U.S. Patent Covering Methods of Treating GA with
Posted: May 04, 2022
Read More
05/04
Iveric Bio Announces Presentation of Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
- Analysis to be Presented at Retinal World Congress in Fort Lauderdale, FL on May 13, 2022 - PARSIPPANY, N.J. --(BUSINESS WIRE)--May 4, 2022-- IVERIC Bio, Inc. (Nasdaq: ISEE) announced today that a post-hoc analysis evaluating the reduction in geographic atrophy (GA) lesion growth observed in
Posted: May 04, 2022
Read More
05/03
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--May 3, 2022-- IVERIC Bio, Inc. (NASDAQ: ISEE) today reported that on May 2, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees.
Posted: May 03, 2022
Read More
04/27
Iveric Bio to Report First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 4, 2022
PARSIPPANY, N.J. --(BUSINESS WIRE)--Apr. 27, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022 . Following the announcement, the Iveric Bio management team will host a live conference call and
Posted: April 27, 2022
Read More
04/26
Iveric Bio to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
PARSIPPANY, N.J. --(BUSINESS WIRE)--Apr. 26, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022 , at 9:00 a.m.
Posted: April 26, 2022
Read More
04/01
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Apr. 1, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on April 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 21 newly-hired, non-executive employees.
Posted: April 01, 2022
Read More
03/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J. --(BUSINESS WIRE)--Mar. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 1, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to four newly-hired, non-executive employees.
Posted: March 02, 2022
Read More
02/28
Iveric Bio to Present at the Cowen 42nd Annual Health Care Conference
PARSIPPANY, N.J. --(BUSINESS WIRE)--Feb. 28, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer, will participate in a fireside chat at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 , at 11:10 a.m. Eastern Time .
Posted: February 28, 2022
Read More
02/24
Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results
- Zimura ® GATHER2 Topline Data Expected in the Second Half of 2022 - - GATHER2 Trial Completion at 84% for Year One; Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate Target Greater than 90% – - Internal Efforts for Preparation of a New Drug Application
Posted: February 24, 2022
Read More
02/17
Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022
NEW YORK --(BUSINESS WIRE)--Feb. 17, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022 . Following the announcement, the Iveric Bio management team will host a live
Posted: February 17, 2022
Read More
02/11
Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
- Analysis Further Highlights the Potential for Zimura to Slow the Progression of Disease and Preserve Foveal Anatomy while Sparing the Foveal Center in Patients with GA - NEW YORK --(BUSINESS WIRE)--Feb. 11, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today a post-hoc analysis which evaluated
Posted: February 11, 2022
Read More
02/07
Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022
NEW YORK --(BUSINESS WIRE)--Feb. 7, 2022-- IVERIC Bio, Inc. (Nasdaq: ISEE) announced today that new post-hoc analyses from the GATHER1 Zimura ® (avacincaptad pegol) Phase 3 clinical trial for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration will be presented at
Posted: February 07, 2022
Read More
02/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Feb. 2, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on February 1, 2022 , the Company granted an equity-based award pursuant to the Company’s 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee.
Posted: February 02, 2022
Read More
01/06
Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors
- Extensive Track Record in U.S. and Global Product Launches and Supply Chain Management - NEW YORK --(BUSINESS WIRE)--Jan. 6, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Christine Ann Miller to its Board of Directors, effective immediately.
Posted: January 06, 2022
Read More
01/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Jan. 4, 2022-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on January 3, 2022 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.
Posted: January 04, 2022
Read More
01/04
Iveric Bio to Present at the H.C. Wainwright BioConnect Virtual Conference
NEW YORK --(BUSINESS WIRE)--Jan. 4, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference , being held virtually from January 10-13, 2022 .
Posted: January 04, 2022
Read More
12/13
Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer
– Highly-Recognized Operational Executive and Strategic Advisor to Biotechnology Companies with a Proven Track Record – NEW YORK --(BUSINESS WIRE)--Dec. 13, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and
Posted: December 13, 2021
Read More
12/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Dec. 2, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 1, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees.
Posted: December 02, 2021
Read More
11/10
Iveric Bio to Participate in the Stifel 2021 Virtual Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Nov. 10, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at
Posted: November 10, 2021
Read More
11/09
Iveric Bio Reports Third Quarter 2021 Operational Highlights and Financial Results
- Zimura ® GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% - - Preparations of a New Drug Application (NDA) and Building Commercial Infrastructure are Underway for a Potential Launch of Zimura for the Treatment of Geographic
Posted: November 09, 2021
Read More
11/03
Iveric Bio to Participate in the Credit Suisse 30th Annual Virtual Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Nov. 3, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Credit Suisse 30 th Annual Virtual Healthcare Conference on Tuesday,
Posted: November 03, 2021
Read More
11/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Nov. 2, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on November 1, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.
Posted: November 02, 2021
Read More
11/02
Iveric Bio to Report Third Quarter 2021 Financial Results and Host Conference Call on Tuesday, November 9, 2021
NEW YORK --(BUSINESS WIRE)--Nov. 2, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2021 financial and operating results on Tuesday, November 9, 2021 . Following the announcement, the Iveric Bio management team will host a live conference call and
Posted: November 02, 2021
Read More
10/21
Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock
NEW YORK --(BUSINESS WIRE)--Oct. 21, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $16.75 per share, less underwriting discounts and commissions.
Posted: October 21, 2021
Read More
10/21
Iveric Bio Announces Proposed Offering of Common Stock
NEW YORK --(BUSINESS WIRE)--Oct. 21, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $125.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30
Posted: October 21, 2021
Read More
10/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Oct. 4, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on October 1, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.
Posted: October 04, 2021
Read More
09/10
Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK --(BUSINESS WIRE)--Sep. 10, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright 23 rd Annual Global Investment Conference , being held virtually from September 13-15, 2021 .
Posted: September 10, 2021
Read More
09/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Sep. 2, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
Posted: September 02, 2021
Read More
08/10
Iveric Bio to Present at the H.C. Wainwright Ophthalmology Virtual Conference
NEW YORK --(BUSINESS WIRE)--Aug. 10, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021 .
Posted: August 10, 2021
Read More
08/04
Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021
NEW YORK --(BUSINESS WIRE)--Aug. 4, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in the panel discussion, “Only Have Eyes For You - Ophthalmic Gene Therapy,” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday,
Posted: August 04, 2021
Read More
08/04
Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
- FDA Agreement Under Special Protocol Assessment (SPA) Received for GATHER2 Phase 3 Clinical Trial of Zimura ® in Geographic Atrophy Secondary to Age-Related Macular Degeneration – - Zimura GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of
Posted: August 04, 2021
Read More
08/03
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Aug. 3, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on August 2, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to five newly hired employees. The inducement grants were approved by the
Posted: August 03, 2021
Read More
07/28
Iveric Bio to Report Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
NEW YORK --(BUSINESS WIRE)--Jul. 28, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021 . Following the announcement, the Iveric Bio management team will host a live conference call and
Posted: July 28, 2021
Read More
07/26
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
- Topline Data Expected in 2H 2022; if Positive, New Drug Application Expected - NEW YORK --(BUSINESS WIRE)--Jul. 26, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced the early completion of patient enrollment of GATHER2, the Company’s second pivotal clinical trial of Zimura ® (avacincaptad
Posted: July 26, 2021
Read More
07/19
Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
– Former U.S. Franchise Head of Ophthalmics at Novartis Brings a Proven Track Record in Major Retinal Product Launches – NEW YORK --(BUSINESS WIRE)--Jul. 19, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial
Posted: July 19, 2021
Read More
07/12
IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
NEW YORK --(BUSINESS WIRE)--Jul. 12, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions.
Posted: July 12, 2021
Read More
07/12
IVERIC bio, Inc. Announces Proposed Offering of Common Stock
NEW YORK --(BUSINESS WIRE)--Jul. 12, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase
Posted: July 12, 2021
Read More
07/06
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- GATHER2 Enrollment and Retention Continue to Exceed Expectations; Completion of Enrollment Expected Late July of this Year and Topline Data Expected Second Half of 2022 - - Conference Call and Webcast Today, July 6, 2021 , at 8:00 a.m. ET   - NEW YORK --(BUSINESS WIRE)--Jul.
Posted: July 06, 2021
Read More
06/18
Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
- GATHER2 Enrollment Nears Completion; Timeline Accelerated to Late July of this Year - - GATHER2 Retention Exceeding Expectations; with Injection Fidelity Rate Target for GATHER2 Greater than 90% - - GATHER1 18 Month Post-Hoc Analyses Show that Zimura 2 mg Has the Potential to Have an Impact on
Posted: June 18, 2021
Read More
06/09
Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021
- To Provide Updates on Zimura ® GATHER2 Enrollment and Retention - - Post-Hoc Analyses from GATHER1 on Progression of Drusen and Nascent Geographic Atrophy to be Presented for the First Time – NEW YORK --(BUSINESS WIRE)--Jun. 9, 2021-- IVERIC bio, Inc.
Posted: June 09, 2021
Read More
05/05
Iveric Bio Reports First Quarter 2021 Operational Highlights and Financial Results
- GATHER2 On-Track to Complete Enrollment in 3Q of this Year - - Conference Call and Webcast Today, May 5, 2021 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--May 5, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the quarter ended March 31, 2021 and
Posted: May 05, 2021
Read More
05/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--May 4, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on May 3, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to four newly hired, non-executive employees.
Posted: May 04, 2021
Read More
04/28
Iveric Bio to Report First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
NEW YORK --(BUSINESS WIRE)--Apr. 28, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021 . Following the announcement, the Iveric Bio management team will host a live conference call and webcast
Posted: April 28, 2021
Read More
04/05
David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund
NEW YORK --(BUSINESS WIRE)--Apr. 5, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer , MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on
Posted: April 05, 2021
Read More
04/01
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Apr. 1, 2021-- IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on April 1, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.
Posted: April 01, 2021
Read More
03/16
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Mar. 16, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 15, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.
Posted: March 16, 2021
Read More
03/03
Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
- Patient Enrollment for GATHER2 Clinical Trial of Zimura® for the Treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration Ahead of Target and Progressing Well; Completion of Enrollment Expected in 3Q of this Year - - Conference Call and Webcast Today, March 3, 2021 , at 8:00
Posted: March 03, 2021
Read More
03/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Mar. 2, 2021-- IVERIC bio, Inc. (Nasdaq:ISEE) today reported that on March 1, 2021 , the Company granted non-statutory stock options to purchase an aggregate of 41,500 shares of the Company’s common stock to 2 newly hired, non-executive employees.
Posted: March 02, 2021
Read More
02/25
Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
NEW YORK --(BUSINESS WIRE)--Feb. 25, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President, and Pravin U. Dugel, M.D., Chief Strategy and Business Officer, will participate in a fireside chat at the Cowen 41 st Annual Health Care
Posted: February 25, 2021
Read More
02/24
Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021
NEW YORK --(BUSINESS WIRE)--Feb. 24, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021 . Following the announcement, the Iveric Bio management team will host a live conference
Posted: February 24, 2021
Read More
01/05
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Jan. 5, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021 , the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees.
Posted: January 05, 2021
Read More
12/17
Iveric Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Dec. 17, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President, will present an overview of the Company at the 39 th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14,
Posted: December 17, 2020
Read More
12/04
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Dec. 4, 2020-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 3, 2020 , the Company granted a newly hired employee equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan. The inducement grants were approved by the Company’s
Posted: December 04, 2020
Read More
11/02
Iveric Bio Reports Third Quarter 2020 Operational Highlights and Financial Results
- Conference Call and Webcast Today, November 2, 2020 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Nov. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.
Posted: November 02, 2020
Read More
10/29
Iveric Bio to Participate in Upcoming Virtual Investor / Industry Conferences
NEW YORK --(BUSINESS WIRE)--Oct. 29, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following, upcoming, virtual investor conferences in November: 29 th Annual Credit Suisse Virtual Healthcare Conference Glenn P.
Posted: October 29, 2020
Read More
10/26
Iveric Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 2, 2020
NEW YORK --(BUSINESS WIRE)--Oct. 26, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020 . Following the announcement, the IVERIC bio management team will host a live conference call and
Posted: October 26, 2020
Read More
10/02
Iveric Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Oct. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on October 1, 2020 , the Company granted a newly hired employee a non-statutory option to purchase 14,000 shares of the Company’s common stock. This grant was made pursuant to the Company’s 2019
Posted: October 02, 2020
Read More
09/03
Iveric Bio to Participate in Upcoming September Investor / Industry Conferences
NEW YORK --(BUSINESS WIRE)--Sep. 3, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September: Citi 15 th Annual BioPharma Virtual Conference 2020 on Wednesday, September 9 and Thursday, September 10,
Posted: September 03, 2020
Read More

Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More